Dr Girard on Nivolumab Plus Relatlimab and Chemotherapy in Stage IV or Recurrent NSCLC

Nicolas Girard, MD, professor, respiratory medicine, Versailles Saint Quentin University; head, Curie-Montsouris Thorax Institute, chair, Medical Oncology Department, Institut Curie, discusses findings from the phase 2 RELATIVITY-104 trial (NCT04623775) investigating nivolumab plus relatlimab-rmbw (Opdualag) and platinum-doublet chemotherapy in patients with previously untreated stage IV or recurrent non–small cell lung cancer (NSCLC).

Disclosures: Dr Girard reports consulting or advisory roles with AbbVie, Amgen, AstraZeneca, BeiGene, Bristol Myers Squibb, Daiichi Sankyo, Gilead Sciences, Ipsen, Janssen, Leo Pharma, Lilly, MSD, Novartis, Pfizer, Roche, Sanofi, and Takeda; travel, accommodations, and expenses support from Janssen and Roche; and research funding from AstraZeneca, Bristol Myers Squibb, MSDavenir, and Roche.